Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2001
Volume 25
Issue 10

The author proposes a strategy for achieving a successful partnership with Big Pharma on the basis of forming a relationship with the company, deliberately managing the alliance, and clearly defining roles and responsibilities.

External Link - article-4522.pdf

Articles in this issue
Outsourcing Outlook
Effects of Polyethylene Glycol on Morphology, Thermomechanical Properties, and Water Vapor Permeability of Cellulose Acetate-Free Films
Hydrogels for the Controlled Release of Pharmaceutical Proteins
Near-Infrared Inspection Complements Other QC Systems
Safety and Manufacturing Standards
System Optimization for In Situ Fiber-Optic Dissolution Testing: Hydrodynamic Effects, System Performance, and Applications
Current Status of the Oral Delivery of Insulin
Laboratory Equipment Qualification
Filter Integrity Testing in Liquid Applications, Revisited, Part I
360&#176 Feedback &#45 Improving the Selection Process All the Way Around
Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers
Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content
Brain Injury, Blood in Injured Brains (stroke, brain hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, brain aneurysm rupture, traumatic brain injury) | Image Credit: © Arugula Pica - stock.adobe.com

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Patrick Lavery
July 9th 2025
Article

Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

medicine and vision concept - woman closeup and eye diagram, future technologies | Image Credit: ©Julia - stock.adobe.com

Advanced Solutions for Sustained Delivery of Ocular Therapies

Cynthia A. Challener
July 4th 2025
Article

Hydrogels, drug-eluting contact lenses, and other implant technologies show real promise.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Sterile capsules for injection. Bottles on the bottling line of the pharmaceutical plant. Machine after checking sterile liquids. Interferon, nasoferon. | Image Credit: © neznamov1984 - stock.adobe.com

ten23 health Joins Gerresheimer, SCHOTT, Stevanato Group in ‘Alliance for RTU’

Patrick Lavery
July 1st 2025
Article

The partnership was formed in September 2024 in response to increasing demand for aseptic filling technologies and processes.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

Susan Haigney
June 30th 2025
Article

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.